Hypofractionated ablative radiotherapy for locally advanced pancreatic cancer

Christopher H Crane, Christopher H Crane

Abstract

The role of radiation in locally advanced unresectable pancreatic cancer (LAPC) is controversial. Randomized trials evaluating standard doses of chemoradiation have not shown a significant benefit from the use of consolidative radiation. Results from non-randomized studies of 3-5-fraction stereotactic body radiotherapy (SBRT) have been similar to standard chemoradiation, but with less toxicity and a shorter treatment time. Doses of SBRT have been reduced to subablative levels for the sake of tolerability. The benefit of both options is unclear. In contrast, ablative doses can be delivered using an SBRT technique in 15-28 fractions. The keys to the delivery of ablative doses are computed tomography (CT) image guidance and respiratory gating. Higher doses have resulted in encouraging long-term survival results. In this review, we present a comprehensive solution to achieving ablative doses for selected patients with pancreatic tumors by using a combination of classical, modern and novel concepts of radiotherapy: fractionation, CT image guidance, respiratory gating, intentional dose heterogeneity, and simultaneous integrated protection.

Keywords: IGRT; SBRT; ablative; locally advanced; pancreatic cancer; respiratory gating.

© The Author 2016. Published by Oxford University Press on behalf of The Japan Radiation Research Society and Japanese Society for Radiation Oncology.

Figures

Fig. 1.
Fig. 1.
Simultaneous Integrated Boost (SIB) and Simultaneous Integrated Protection (SIP) in the Treatment Planning of Locally Advanced Pancreatic Cancer. This figure illustrates the proximity of gastrointestinal organs to a pancreatic tumor. This patient was treated with a dose of 70 Gy in 28 fractions to the GTV and 98 Gy to the hypoxic center, using feedback-assisted inspiration breath-hold gating and daily diagnostic-quality CT imaging to verify stomach position. GTV = gross tumor volume. S = stomach, J = jejunum, D = duodenum, C = colon, PV = collaterals from an occluded portal vein.
Fig. 2.
Fig. 2.
Daily CT image guidance allows monitoring of the stomach and small bowel. Daily CT image guidance is an essential component of the safe delivery of ablative doses of radiation to a tumor surrounded by gastrointestional luminal structures. An inspiration breath-hold technique is used to control respiratory motion. The intravenous contrast-enhanced simulation scan on the right is registered with the daily CT scan on the left for verification of luminal organ position. The daily CT can be used for adaptive planning if internal organ position is consistently different from that in the simulation CT.

References

    1. Hammel P HF, Huguet F, van Laethem J-L. Comparison of chemoradiotherapy and chemotherapy in patients with a locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: final results of the international phase III LAP 07 study. ASCO 2013 Annual Meeting; abstract LBA4003, 2013.
    1. Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. Gastrointestinal Tumor Study Group. J Natl Cancer Inst 1988;80:751–5.
    1. Chauffert B, Mornex F, Bonnetain F et al. . Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000–01 FFCD/SFRO study. Ann Oncol 2008;19:1592–9.
    1. Klaassen DJ, MacIntyre JM, Catton GE et al. . Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil—an Eastern Cooperative Oncology Group study. J Clin Oncol 1985;3:373–8.
    1. Loehrer PJ, Feng Y, Cardenes H et al. . Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol 2011;29:4105–12.
    1. Kindler HL, Niedzwiecki D, Hollis D et al. . Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 2010;28:3617–22.
    1. Philip PA, Benedetti J, Corless CL et al. . Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group–directed intergroup trial S0205. J Clin Oncol 2010;28:3605–10.
    1. Poplin E, Feng Y, Berlin J et al. . Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2009;27:3778–85.
    1. Iacobuzio-Donahue CA, Fu B, Yachida S et al. . DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol 2009;27:1806–13.
    1. Crane CH, Varadhachary GR, Yordy JS et al. . Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression. J Clin Oncol 2011;29:3037–43.
    1. Herman JM, Chang DT, Goodman KA et al. . Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma. Cancer 2015;121:1128–37.
    1. Krishnan S, Chadha AS, Suh Y et al. . Focal radiotherapy dose escalation improves overall survival in locally advanced pancreatic cancer patients receiving induction chemotherapy and consolidative chemoradiation. Int J Radiat Oncol Biol Phys 2015, in press.
    1. Kelly P, Das P, Pinnix CC et al. . Duodenal toxicity after fractionated chemoradiation for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 2013;85:e143–9.
    1. Radiation Therapy Oncology Group (RTOG). NRG-alias Protocol Information. 201: (23 March 2015, date last accessed).

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다